The Quantellect read.As of Nov 19, 2026, 3 active firms cover Rani Therapeutics Holdings Inc: 3 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $5.00 to $11.00 (about 2.2x), a sign of real disagreement on valuation. The average target of $7.33 sits 1057% above the current $0.63. The rating mix has stayed broadly stable, with Buy-side ratings easing from 4 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.05 next quarter toward $-0.19 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy3100%
Neutral00%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$7.33
+1056.9% upside
Average target across 3 active firms as of Nov 19, 2026 vs $0.63 current
Highest Target$11.00
Average Target$7.33
Lowest Target$5.00
Detailed analyst forecasts for RANI
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 3 of 3 active firms rate RANI a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
RANI EPS & revenue forecast
EPS · NEXT QUARTER
$-0.05
Range $-0.05 – $-0.05 · 1 analysts · +25% YoY
Next period, 1 analysts expect Rani Therapeutics Holdings Inc to earn $-0.05 a share (range $-0.05 – $-0.05), versus $-0.04 a year earlier. Full-year consensus is $-0.17, growing to $-0.19 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts · -100% YoY
Revenue is expected to reach $0 (range $0 – $0), -100.0% year-over-year. Full-year consensus is $6.4M, rising to $5.6M next year.
Top analysts covering Rani Therapeutics Holdings Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RANI.
#1
EN
Edward Nash
Canaccord Genuity · Rank #270
Buy
$5.00+688.8% to target
Overall win rate
44%
+ Follow
#2
Mitchell Kapoor
HC Wainwright & Co. · Rank #305
Buy
$9.00+1319.8% to target
Overall win rate
33%
+ Follow
#3
Andreas Argyrides
Oppenheimer · Rank #380
Buy
$4.00+531.0% to target
Overall win rate
41%
+ Follow
#4
BF
Brandon Folkes
HC Wainwright & Co. · Rank #402
Buy
$11.00+1635.3% to target
Overall win rate
38%
+ Follow
#5
Raghuram Selvaraju
HC Wainwright & Co. · Rank #423
Buy
$9.00+1319.8% to target
Overall win rate
36%
+ Follow
RANI stock forecast FAQ
What is RANI's average 12-month price target?+
The 3 active firms with a live target average $7.33 for Rani Therapeutics Holdings Inc over the next 12 months, ranging from a $11.00 high to a $5.00 low, as of Nov 19, 2026.
Is RANI stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for RANI?+
The Street-high target is $11.00 (HC Wainwright & Co.), and the Street-low is $5.00 (Canaccord Genuity). The average of all 3 active-firm targets is $7.33.
How many active Wall Street firms cover RANI?+
3 active firms have a recognized rating on Rani Therapeutics Holdings Inc as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering RANI?+
Among analysts who currently cover RANI, Edward Nash of Canaccord Genuity has the strongest overall Quantellect track record (Rank #270). Their current call is Buy with a $5.00 target.
What is Rani Therapeutics Holdings Inc's projected EPS for next quarter?+
The consensus estimate is $-0.05 per share (range $-0.05 – $-0.05) across 1 analysts. Full-year EPS is projected at $-0.17, rising to $-0.19 the following year.
How much revenue is Rani Therapeutics Holdings Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $6.4M, growing to $5.6M next year.
Have analysts been upgrading or downgrading RANI lately?+
As of Nov 19, 2026, 3 of 3 active firms rate RANI a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RANI calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.